InvestSMART

Orthocell Limited (ASX:OCC)

ALERT: Price-sensitive ASX Announcement for OCC
Current share price for OCC : $0.730 -0.305 (-29.47%)+
Announcement
Release
20 Apr 2026 9:05AM
Price at Release
$1.035
Full Release
download
Summary
Orthocell Limited's Q3 FY26 Investor Presentation highlights significant growth and strategic progress in the commercialization of its medical devices, particularly RemplirTM. The company reported a 45% increase in year-to-date revenue compared to the prior year, reaching A$9.4 million, with robust cash reserves of A$48 million. The U.S. market has shown early success with Remplir, achieving significant hospital and surgeon adoption, contributing to a 40% growth in units sold. The presentation emphasizes Orthocell’s path to profitability by achieving cash breakeven with less than 1% U.S. market penetration. Other strategic initiatives include expanding usage in defense sectors and advancing product pipelines for prostatectomies and tendon repair. The presentation also highlights ongoing market development efforts in Australia, New Zealand, and other international markets.
Key Points
  • Orthocell achieved a 45% increase in year-to-date revenue for Q3 FY26.
  • Robust cash reserves of A$48 million as of March 31, 2026.
  • Significant early success with Remplir in the U.S. market, achieving hospital and surgeon growth.
  • Path to profitability outlined with less than 1% U.S. market share needed for breakeven.
  • Strategic focus on expanding into defense sectors and advancing product pipelines.
  • Continued growth efforts in Australia, New Zealand, and other international markets.
  • First sales in Canada are imminent.
  • Over 300 Australian surgeons are actively using Orthocell's products.
  • Orthocell's collagen platform is approved in nine jurisdictions.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.